Carmen Solórzano named chief of Division of Surgical Oncology at Vanderbilt

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

CARMEN SOLÓRZANO was named chief of the Division of Surgical Oncology and Endocrine Surgery at Vanderbilt University Medical Center. Solórzano is a professor of Surgery and director of the Endocrine Surgery Center.

Solórzano joined the Vanderbilt faculty in 2010 and specializes in endocrine surgery, including neoplasms and cancers of the thyroid, parathyroid and adrenal glands, the pancreas and digestive system, as well as neuroendocrine tumors. She was selected following a national search that included more than 70 potential candidates, according to the center.

In addition to her current role at VUMC, Solórzano has served as chief of General Surgery at the Veterans Administration Hospital since 2012.

Solórzano previously served as assistant professor of surgery at the University of Miami, and later became chief of Endocrine Surgery. She has authored more than 100 publications, has lectured around the world and serves on the editorial boards for several journals.

YOU MAY BE INTERESTED IN

Recently, HHS Secretary Robert F. Kennedy Jr. posted a video montage featuring himself shirtless in jeans, working out with Kid Rock. The duo is in a blue-lit grotto with a cold plunge and sauna. Set to Kid Rock’s “Bawitdaba” and intercut with a selection of patriotic imagery, the video ends with the two men in a hot tub, chugging what appears to be milk.
In January, FDA released a draft guidance entitled “Minimal Residual Disease and Complete Response in Multiple Myeloma: Use as Endpoints to Support Accelerated Approval.” This release came roughly 20 months after the Oncologic Drugs Advisory Committee (ODAC) voted unanimously that minimal residual disease (MRD) negativity, in combination with complete response (CR), is an acceptable primary endpoint to support accelerated approval for multiple myeloma (MM) therapies. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login